MINI FUTURE LONG - ELI LILLY & CO | Market Closed - Euronext Paris 12:30:01 2024-05-15 EDT | ||
| 3.346 EUR | +13.81% |
|
| Current month | +0.18% | ||
| 1 month | +8.44% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-15 | 3.346 | +13.81% |
| 24-05-14 | 2.94 | +0.10% |
| 24-05-13 | 2.937 | -5.90% |
| 24-05-10 | 3.121 | -5.11% |
| 24-05-09 | 3.289 | -1.64% |
Real-time Euronext Paris
Last update May 15, 2024 at 12:30 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| HB7NB | |
| ISIN | NLBNPNL2QAS8 |
| Date issued | 2024-04-10 |
| Strike | 596 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 3.45 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.842 € |
|---|---|
| Lowest since issue | 2.31 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
764
USD
Average target price
850.4
USD
Spread / Average Target
+11.31%
- Stock Market
- Certificates
- HB7NB Certificat
